Harmony Biosciences Holdings, Inc. (HRMY)
Nasdaq · Healthcare · Biotechnology
$39.92+0.71%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.3B
- P/E (trailing)
- 12.9
- Forward P/E
- 5.7
- 52-week range
- $25.52 – $43.49
- 52-week change
- +46.54%
- EPS (trailing)
- $3.10
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $868M (+21.51%)
- Net income
- $159M
- Operating margin
- 24.0%
- Diluted EPS
- $2.71
- Free cash flow
- $348M
From the company’s annual report on SEC EDGAR.
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome.
Headquarters: Plymouth Meeting, United States · 293 employees · harmonybiosciences.com